Menu Back toOversight-in-the-Era-of-E6-R2

DIA 2018 Global Annual Meeting


Oversight in the Era of E6 (R2)

    Session Chair(s)
      Melissa  Bomben, MS

      Melissa Bomben, MS

      • Vice President, Strategic Resourcing
      • Syneos Health, United States
    This session will outline the characteristics that define common outsourcing models and expose their corresponding risk/benefit ratio with regard to sponsor and CRO oversight. Case studies of proven solutions within each model will be presented and linked to recommendations to achieve enhanced oversight in the era of E6 (R2).
    Learning Objective : Discuss the risk/benefit ratio with regard to sponsor and CRO oversight in common outsourcing models; Identify methods to implement improved and more efficient approaches to clinical trial oversight.